Table 2.
Imaging and molecular characteristics in 33 patients diagnosed with butterfly glioblastoma between 01/01/2007 and 31/12/2014
MRI characteristics | |
---|---|
Corpus callosum affectiona | |
Rostrum/genu | 21 (63.6%) |
Body | 25 (75.8%) |
Splenium | 14 (42.4%) |
Tumor distribution | |
Left skewed | 13 (39.4%) |
Right skewed | 13 (39.4%) |
Symmetric | 7 (21.2%) |
Tumor volumes | |
T1-weighted contrast-enhanced MRI (cm3) | 41 (26–73) |
T2-weighted/FLAIR MRI (cm3) | 137 (83–229) |
Ratio T2/FLAIR:T1 volumes | 3.2 (2.4–4.4) |
Hypothalamus involvement | 11 (33.3%) |
Basal ganglia involvement | 14 (42.4%) |
Blood vessel affection | 20 (60.6%) |
Necrosis | 28 (84.8%) |
Flow void | 23 (69.7%) |
Mass effectb | 16 (48.5%) |
Molecular characteristics (n = 11)c | |
MGMT promoter methylation status | |
Inconclusive | 2 (18.2%) |
Methylated | 2 (18.2%) |
Unmethylated | 7 (63.6%) |
BRAF mutational status | |
BRAF V600E mutation | 0 (0.0%) |
BRAF V600E wild type | 11 (100.0%) |
Tumor volumes and T2/FLAIR:T1 ratio presented as median (IQR), all others as absolute numbers (%). Tumor volumes defined as contrast enhancement and necrosis in T1-weighted MRI and tumor associated non-enhancing hyperintense lesions in T2-weighted/FLAIR MRI.
MRI, magnetic resonance imaging; FLAIR, fluid attenuated inversion recovery; cm3, cubic centimeters; MGMT, O(6)-methylguanine-DNA methyltransferase.
aSum exceeding 100% due to the affection of multiple regions in several patients.
bDefined as midline shift ≥ 1 mm.
cPresented as absolute numbers and % of patients with histological sample available for re-evaluation and molecular analyses.